IP Library Granted Patent US 11,547,728
Granted Patent B2
US 11,547,728 · App. 17/412,746 · Granted Jan 10, 2023

CD19-targeted chimeric antigen receptor and use thereof

Inventors: Jianxiang Wang (Tianjin, CN); Min Wang (Tianjin, CN); Lulu Lv (Tianjin, CN); Lin Shi (Tianjin, CN); Na An (Tianjin, CN); Rui Wang (Tianjin, CN); Yun Liu (Tianjin, CN)
Assignee: Juventas Cell Therapy Ltd.
A61K35/17A61P35/02C07K14/70517C07K14/70521C07K14/70578C07K16/2803C07K16/2887C12N15/86C12N5/0636C12N5/0646
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,547,728
App. No.
17/412,746
Granted
Jan 10, 2023
Kind
B2
Abstract

A chimeric antigen receptor, comprising an amino acid sequence shown in SEQ ID NO. 1. A nucleic acid encoding the chimeric antigen receptor, a vector comprising the nucleic acid, an immune effector cell comprising the chimeric antigen receptor, the nucleic acid molecule and/or the vector, a method for preparing the immune effector cell, a composition comprising the immune effector cell, and use of the chimeric antigen receptor.

Claims (8)

1. A chimeric antigen receptor, consisting of the amino acid sequence of in SEQ ID NO. 1.

2. An immune effector cell comprising the chimeric antigen receptor according to claim 1 .

3. The immune effector cell according to claim 2 , wherein the immune effector cell is selected from the group consisting of a T lymphocytes and a natural killer cell.

4. A composition, comprising the immune effector cell according to claim 2 .

5. The composition according to claim 4 , further comprising one or more formulations of carriers, stabilizers, excipients, diluents, solubilizers, surfactants, emulsifiers and preservatives.

6. The composition according to claim 4 , wherein the composition is present in a liquid, frozen, or lyophilized form.

7. The composition according to claim 4 , wherein the immune effector cell is selected from the group consisting of a T lymphocyte and a natural killer cell.

8. The composition according to claim 4 , wherein a chimeric antigen receptor consisting of the amino acid sequence of SEQ ID NO. 1 is expressed on the surface of the immune effector cell.

Assignments (2)
CHANGE OF NAME Recorded Feb 27, 2026
From: JUVENTAS CELL THERAPY LTD.
To: JUVENTAS CO., LTD.
Reel/Frame 073921/0442 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2021
From: WANG, JIANXIANG; WANG, MIN; LV, LULU; SHI, LIN; AN, NA; WANG, RUI; LIU, YUN
To: JUVENTAS CELL THERAPY LTD
Reel/Frame 057302/0033 →
Continuity (2)
Continuation PCTCN2020136241 · Dec 14, 2020
Related Publication 20220040234A1 · Feb 10, 2022
Cited By (1)
US 12,441,779